Fatty liver? Be Activ!

You might not know if you are among the approximately 30 percent of the population suffering from fatty liver disease, the most common liver condition in the Western world. It usually causes no symptoms aside More...

Exalenz Bioscience Launches Study of Breath-Based Diagnostic Test Addressing the $2 Billion NASH Market Potential

– – Israel’s Exalenz Bioscience (TASE: EXEN), a developer and marketer of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, announced More...